Why the study?
Does benidipine or amlodipine reduce major adverse cardiovascular events compared to nifedipine in hypertensive patients with coronary artery disease?
Does benidipine or amlodipine reduce major adverse cardiovascular events compared to nifedipine in hypertensive patients with coronary artery disease?
In hypertensive patients with coronary artery disease, long-acting calcium channel blockers like benidipine and amlodipine may offer superior protection against major adverse cardiovascular events compared to nifedipine, particularly in those with concurrent chronic kidney disease.
May support benidipine preference over nifedipine in hypertensive CAD; leaves open confirmation in RCTs before any practice change.
Calcium channel blockers (CCBs) can prevent cardiovascular events in patients with coronary artery disease (CAD). This study looked retrospectively at the prognosis of CAD in hypertensive patients with CAD who had undergone a coronary angiograph, had been given a CCB (benidipine [n = 66], amlodipine [n = 45], or long-acting nifedipine [n = 31]) on hospital discharge and were then followed up for a mean +/- SD of 5.2 +/- 2.9 years. Systolic/diastolic blood pressure for all 142 patients decreased significantly from a mean +/- SD of 137 +/- 20/74 +/- 15 mmHg to 129 +/- 20/71 +/- 12 mmHg. Major adverse cardiovascular events (MACE) occurred in 15 patients. Chronic kidney disease (CKD) was a significant risk factor for MACE (hazard ratio 2.35, 95% confidence intervals 1.45, 3.80). Benidipine was superior to nifedipine in preventing MACE in patients both with and without CKD. In conclusion, benidipine and amlodipine reduced the frequency of MACE in hypertensive patients with CAD, particularly in those with complicating CKD.
No takes yet. Share an insight, caveat, or question.
Nitta et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: